Renal dysfunction after treatment with isophosphamide (NSC-109724).
D000138:Acidosis / Q000139:chemically induced; D000477:Alkylating Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000596:Amino Acids / Q000652:urine; D001798:Blood Proteins / Q000032:analysis; D001806:Blood Urea Nitrogen; D001943:Breast Neoplasms / Q000188:drug therapy; D003404:Creatinine / Q000652:urine; D003498:Cyclic P-Oxides / Q000009:adverse effects* / Q000627:therapeutic use; D005021:Ethylamines / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006029:Glycosuria / Q000139:chemically induced; D006801:Humans; D007659:Ketones / Q000652:urine; D007671:Kidney Concentrating Ability; D007674:Kidney Diseases / Q000139:chemically induced*; D007677:Kidney Function Tests; D007678:Kidney Glomerulus / Q000503:physiopathology; D007684:Kidney Tubules / Q000503:physiopathology; D008875:Middle Aged; D009994:Osmolar Concentration; D010078:Oxazines / Q000009:adverse effects* / Q000627:therapeutic use; D010710:Phosphates / Q000652:urine; D011507:Proteinuria / Q000139:chemically induced; D013997:Time Factors
D000477:Alkylating Agents; D000596:Amino Acids; D001798:Blood Proteins; D003498:Cyclic P-Oxides; D005021:Ethylamines; D007659:Ketones; D010078:Oxazines; D010710:Phosphates; D003404:Creatinine